Logo image of MDG1.DE

MEDIGENE AG (MDG1.DE) Stock Price, Quote, News and Overview

FRA:MDG1 - Deutsche Boerse Ag - DE000A40ESG2 - Common Stock - Currency: EUR

0.1335  -0.05 (-27.64%)

MDG1.DE Quote, Performance and Key Statistics

MEDIGENE AG

FRA:MDG1 (4/29/2025, 7:00:00 PM)

0.1335

-0.05 (-27.64%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.39
52 Week Low0.08
Market Cap1.99M
Shares14.89M
Float0
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-12 2025-08-12
IPO06-30 2000-06-30


MDG1.DE short term performance overview.The bars show the price performance of MDG1.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

MDG1.DE long term performance overview.The bars show the price performance of MDG1.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of MDG1.DE is 0.1335 EUR. In the past month the price decreased by -91.1%. In the past year, price decreased by -91.36%.

MEDIGENE AG / MDG1 Daily stock chart

MDG1.DE Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 17.34 280.91B
AMG.DE AMGEN INC 12.74 126.80B
1GILD.MI GILEAD SCIENCES INC 13.4 115.15B
GIS.DE GILEAD SCIENCES INC 12.89 110.69B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 95.85B
1REGN.MI REGENERON PHARMACEUTICALS 11.83 52.64B
ARGX.BR ARGENX SE 101.84 29.66B
22UA.DE BIONTECH SE-ADR N/A 19.98B
IDP.DE BIOGEN INC 7.64 15.80B
1MRNA.MI MODERNA INC N/A 8.45B
0QF.DE MODERNA INC N/A 8.12B
BIO.DE BIOTEST AG 65.54 1.69B

About MDG1.DE

Company Profile

MDG1 logo image MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. The company is headquartered in Planegg, Bayern and currently employs 86 full-time employees. The company went IPO on 2000-06-30. The firm focuses on the development of personalized T cell-based immunotherapies. The company develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The firm operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.

Company Info

MEDIGENE AG

Lochhamer Strasse 11

Planegg BAYERN DE

Employees: 87

MDG1 Company Website

MDG1 Investor Relations

Phone: 49892000330

MEDIGENE AG / MDG1.DE FAQ

What is the stock price of MEDIGENE AG today?

The current stock price of MDG1.DE is 0.1335 EUR. The price decreased by -27.64% in the last trading session.


What is the ticker symbol for MEDIGENE AG stock?

The exchange symbol of MEDIGENE AG is MDG1 and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is MDG1.DE stock listed?

MDG1.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for MEDIGENE AG stock?

8 analysts have analysed MDG1.DE and the average price target is 3.88 EUR. This implies a price increase of 2803.37% is expected in the next year compared to the current price of 0.1335. Check the MEDIGENE AG stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MEDIGENE AG worth?

MEDIGENE AG (MDG1.DE) has a market capitalization of 1.99M EUR. This makes MDG1.DE a Nano Cap stock.


How many employees does MEDIGENE AG have?

MEDIGENE AG (MDG1.DE) currently has 87 employees.


Is MEDIGENE AG (MDG1.DE) expected to grow?

The Revenue of MEDIGENE AG (MDG1.DE) is expected to grow by 100% in the next year. Check the estimates tab for more information on the MDG1.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MEDIGENE AG (MDG1.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MEDIGENE AG (MDG1.DE) stock pay dividends?

MDG1.DE does not pay a dividend.


When does MEDIGENE AG (MDG1.DE) report earnings?

MEDIGENE AG (MDG1.DE) will report earnings on 2025-08-12.


What is the Price/Earnings (PE) ratio of MEDIGENE AG (MDG1.DE)?

MEDIGENE AG (MDG1.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.25).


MDG1.DE Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

MDG1.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MDG1.DE. The financial health of MDG1.DE is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MDG1.DE Financial Highlights

Over the last trailing twelve months MDG1.DE reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS decreased by -94.19% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -56.15%
ROE -82.28%
Debt/Equity 0.08
Chartmill High Growth Momentum
EPS Q2Q%-91.4%
Sales Q2Q%-6%
EPS 1Y (TTM)-94.19%
Revenue 1Y (TTM)-80.69%

MDG1.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to MDG1.DE. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of 38.46% and a revenue growth 100% for MDG1.DE


Ownership
Inst Owners2.38%
Ins Owners3.36%
Short Float %N/A
Short RatioN/A
Analysts
Analysts82.5
Price Target3.88 (2806.37%)
EPS Next Y38.46%
Revenue Next Year100%